Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Building a Cancer Medtech Company the Hard Way: Shaun Bagai on Evidence, Strategy, and Growth

Mar 12, 202633 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Drug launches in oncology don’t succeed simply because the technology works; they succeed when the evidence is strong enough to change physician behavior. In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Shaun Bagai, CEO of RenovoRx, to discuss the long and uncertain journey of building a medtech company grounded in clinical proof. From turning down medical school to leading a Nasdaq-listed oncology company, Shaun shares how physician feedback reshaped the company’s strategy, why investing in rigorous clinical trials can be a defining leadership decision, and why face-to-face relationships remain essential for market adoption in healthcare. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00In fact, I remember talking to an advisor years ago, and they said, you know, we'll look back like 50 years from now, it'd be less than that time, and think about how barbaric we were. You know, how do you treat this ailment? Well, you blast the entire body with poison and hope some gets the tumors. Nope, not the way to go. So for whatever reason, we haven't really focused on this.

SPEAKER_02Hello, hello, and welcome to Pharma Sessions, a place for pharmaceutical leaders to come and learn from each other. I'm your host, Jonathan Kaske. Technology and market trends are bringing change at an ever accelerating rate, and no person, team, or company can afford to be left behind. Here, we dive into the strategies and tactics that our guests use to tackle these challenges and create new opportunities and how you can do the same in your own organization.

SPEAKER_02This episode of Pharma Sessions is sponsored by Xunt, makers of the X1 reporting platform. On today's episode of Pharma Sessions, I'm thrilled to welcome Sean Bagay, CEO of Renovo RX, a NASDAQ listed oncology company pioneering targeted drug delivery through its trans arterial microperfusion platform. How did I do, Sean? Did I get that right? Perfect. Okay. So Sean spent his career at the intersection of innovation and commercialization from early stage startups to large medtech organizations like Medtronic and Heartflow.

SPEAKER_02And I think what makes this journey especially compelling is the path turning down medical school, which we'll get into, turning to the world of building technologies that impact patients at scale, leading Renovo Rx now for over a decade from prototype stage to phase three trials commercialization. So a lot of exciting stuff. We'll talk about entrepreneurship, disruptive oncology innovation, many other things. With that, welcome to the show. Thank you, John. I appreciate the opportunity. Absolutely. So before we get into the meat of it, I always like to start with a little icebreaker.

SPEAKER_02And it's uh roughly morning time there on the West Coast. What have you had to eat so far today?

SPEAKER_00My breakfast at Champions is actually a protein shake with an espresso shot. So that's what that's so far.

SPEAKER_02Right. And that's maximum efficiency of uh caffeine without even having to break pace. So I like it. All right. So tell the people a little bit about yourself. I know I'd alluded to it. You this kind of started this journey, maybe thinking you were going to be a doctor, but what's sort of your background and what the path that's led you to today?

SPEAKER_00Well, I appreciate questions here, John. I've I've been passionate about business my whole life and medicine. Uh, I'd say as a child when I was just in a back injury playing football. And I got interested in medicine back then. And also I've got a lot of doctors in the family on one side of the family and a lot of business people on the other side of the family. So I think uh hopefully taking the best of both worlds. I've been able to have the lucky happenstance to drive medical technologies on a business standpoint that really has made a big impact on patients and medical care to date. And I'd like the biggest impact we could potentially have is here at River of Rx.

SPEAKER_02So let's just pause there for a second. You said you were interested in becoming a doctor and you ended up not doing that. Was what was there a particular transition that made you make that decision or a particular point that led you to that?

SPEAKER_00Absolutely. I'm very uh determined. And and uh from a young age, I thought I'll be a physician and do everything you can to get there. So take you to the MCATS, taking time off college sports, if you will, to study and driving to the point I got accepted to med school and did a one-year internship when I was applying between college and what would have been med school at a medical device startup company. And the founder, CEO actually had driven me to make a tough decision of maybe staying on the industry versus going on to med school.

SPEAKER_00As much as he was an MD, he didn't practice medicine and he'd built companies and has built several successful since. And really it imparted on me as an entrepreneur, one could actually have a bigger impact on patients' lives by building and driving new therapies and technologies than a single position possibly could. So it was a shift where I still get to do what I love doing on driving medical care in a sense of inventing or helping build new companies and technologies, yet I get the business aspect as well and the impact at the same time.

SPEAKER_00That's really interesting.

SPEAKER_02So it's almost funny to me how much happenstance kind of plays into this, where this is a fairly momentous life trajectory type decision that you're making, but you're you're uh essentially presenting it as this was, you know, you happen to get an internship with this person rather than the company down the street, which might not have had nearly the same impact on your thoughts of medicine and how to impact patients.

SPEAKER_00Absolutely. It's it's interesting. So I feel like I've made several tough decisions along my career choices and school choices that would seem very counterintuitive to most people, but but end up working out really well. So I've gotten lucky in a sense that that these situations have happened since it worked out. And even that CEO who told me that came by way of an internship I did in college at Stanford Animal Labs, doing medical research for a year and happened to run across this company while doing my internship and happened to meet the management there who said, Hey, uh, while you're waiting to get into med school, why don't you come work with us for a year?

SPEAKER_00So a lot of lucky pieces along the way. And as my stepmom likes to say, well, I put myself in front of good opportunities and good things happen. There you go.

SPEAKER_02So between that moment and we'll get we'll spend a good chunk of time talking about your experience over the last 10 years at Renovo. But what was your experience in between those times, in between joining or starting Renovo and that moment that you're talking about?

SPEAKER_00So that first company is called Transvascular. I spent the first year on the preclinical research RD side helping drive the innovation aspect of the business, both from a very inexperienced entry-level position uh into driving running a lot of the RD programs. And as my then CEO mentored me on, I was able to push myself into eventually running the clinical trials for the whole company and was manager of clinical research before we got acquired by Medtronic. And then at Medtronic, I was pushed uh by my mentors to go get a sales experience, which would be very helpful on someday building and running companies.

SPEAKER_00So I transitioned over a couple of years to train the physicians and the sales reps around the country on the technology on how to treat patients with the catheter they bought, and then transitioned in the sales role for about five years at Medtronic, launching disruptive products like their first drug-coded corridor scent, which is now obviously a commodity, but many years ago, it was an amazing innovation to keep arteries open for that long and now it's uh commonplace, which is great. From there, I went to another startup company called Ardean, where we invented and developed a new technology to treat blood pressure using a device versus many, many medications, and much more successfully.

SPEAKER_00That company was successful earlier on and got acquired by Medtronic again for about a billion dollars back in 2012. Exactly, exactly. In fact, Medtronic and then invested by a nice company, Harpwill, which you may have heard of as well. It's a diagnostic for coronary artery disease, non-invasive and probably more accurate than most diagnostic tests. Another amazing disruptive technology that's been successful since I was there. And what stage was did you found Renovo or what stage was it when you joined? So it was two people essentially back when I joined in 2014.

SPEAKER_00Uh, Dr. Ram Tanaga, the invention of the technology, co-founded the company in 2009. It was your typical Silicon Valley garage project, bootstrapped for the first several years before they got first funding in 2013. So I took over a year and a half into kind of it becoming an incorporated real company, albeit tiny. And they hired me as CEO once a previous CEO stepped down. So when I came in, they had just applied to the FDA for 510K clearance of the device, just filed their first patent, and now I've got about, I think, 19 issued internationally.

SPEAKER_00And had never used this on a patient before, just finished the prototyping of the device. So it was definitely a very early stage company that I helped build out. Now that being there for 11 and a half years and building a lot of progress and value and now reaching many patients already, the founder effectually calls me a mini pounder. No, it didn't round it, but I was there very founded.

SPEAKER_02But when you join at uh with an organization with two people, I feel like that is that counts, right? In that, there must be a lot there, but I'm just curious. I mean, it sounds like you had a fairly, you know, successful and stable career of joining these companies, going to Medtronic, leaving, going back to Medtronic acquisitions, right? How did this come across your radar? And how did you decide that this was a good idea to go and be person number three here versus leaving what I can only assume was a fairly attractive and stable job?

SPEAKER_00It was a combination, so of seeing headwinds come into place at Hardflow and having the opportunity here. So at Hardflow, I joined them, I'd say almost 15 years prematurely to commercialize them. Uh, the technology wasn't quite ready yet. They were just wrapping up a clinical trial that was unsuccessful, and they hired me to take them from clinical to sales, which is what I my strong suit is. And when that happened, they said, Look, you're got a lot of talent. You're an expert in clinical research. And they kept me on board. And I think they let my boss go at the time, who's really ahead of sales and marketing.

SPEAKER_00So I was became the global marketing or global uh director of market development. So I transitioned them from clinical research into commercial to some degree. So I ended up running their next major clinical trial uh like a salesperson would. The notion of let's get this enrolled as fast as possible, meet with the physicians face to face. I lived on an airplane. I spent most of my time uh Japan, Europe, and South Korea, I believe, at the time as well. And so I did two things. One was market development, and in parallel drive the clinical trial to success. And then when we started wrapping up the trial, the data was looking very good.

SPEAKER_00A lot of my efforts ended up resulting in what's now Hartflow, Japan. So I spent, uh, I think it was in Japan maybe twice a month, met with the regulatories there, the reimbursement specialists, built a consulting team, put together advisory boards of physicians. And at that time, we decided let's hire a local team in Japan. So it was time to turn focus back to the US when they're applying for FDA approval for the technology. And I saw the reimbursement headwinds would make it very difficult to get the product and technology adopted anytime quick. It's now happened the last few years.

SPEAKER_00So I did see them almost stagnant for many years while building out Renovo. And roughly around the same time, Dr. Ramton Agata, founder of our technology, tapped me in the shoulder. And I've known him through two different companies previously, now for almost 30 years. And he said, look, this is a perfect sweet spot for you. It's clinical research, transitioning to sales, the market adoption, it's disruptive, it's challenging. This will change the face of cancer care. And this is ripe for you to take over and build this out as your first CEO opportunity. So it was perfect timing, both the company and the state it was, and then and for my career growth as well, to take this on about 11 and a half years ago.

SPEAKER_02And so you're you're really talking about a journey from an early prototype to phase three trial to commercialization. Was there a moment or maybe multiple moments that kind of felt like true turning points for the organization during that time period?

SPEAKER_00Yeah, I'm not sure how long this podcast is. I can talk about it for about six hours on true turning points the company. But I'll highlight the top ones. It's been an amazing journey so far because I look back sometimes when I do investor updates or now the Republic, I do uh earnings calls and whatnot. I think about what we've accomplished in three months. And I could say every three months, we probably have one or two major turning points, and it never stops. It's been that way for 11 and a half years, which is why this is probably the most interesting job I've ever had in my career. But I think that the major reflections we've had is, and some of them were barriers, some were roadblocks, and that's part of my personality.

SPEAKER_00And the fun for me is hitting those roadblocks and challenges and finding ways to overcome them. Early on, we believe strongly that if we change the way that chemotherapy is delivered by localizing it and reducing side effects and showing some benefit of efficacy, that should be enough to turn the minds of physicians to start using our technology in a space like pancreatic cancer, where nothing is working. There's no better alternative than try something new. In fact, in the guidelines, as much as chemotherapy and radiation are first line therapy guidelines, it says in more than one place, first line therapy should go do a clinical trial because they know that none of this stuff actually works.

SPEAKER_00So, with that, we hit our barrier because we did some early cases. We did a dose escalation safety study. We showed that the technology seemed to be safe, and we had some patients respond very well. So patients who would normally pass away after six, twelve, fifteen months. Our first patients lived two and a half almost just over three years, some some of them. So we saw this great technology. So we actually had tried to look at commercialization and do a post-market registry with some initial traction, but we couldn't get deep adoption with our first customers. This is back in 2016, 17. And what did you figure out why that was?

SPEAKER_00We did, and that's what's something I've always worked with physicians closely. And the oncologist said, look, there's nothing to tell me I should refer my patients to this. I shouldn't change my practice for I learned in med school, what I learned in training, because sure it looks promising, but there's not empirical, head-to-head randomized data saying change this, which is true of most technologies for adoption.

SPEAKER_02So are they referring to guidelines or just individual, just studies that you can have your reps, rep sharing with them? Are they looking for actual guidelines saying, hey, evidence-based medicine, go this direction?

SPEAKER_00It's honestly one of the same, especially in cancer, because it was the latter. It's the evidence-based medicine, show me clinical trials. And when you do that, that actually gets in the guidelines. So it's one and or the other, but they usually go hand in hand. And so with that, we designed a very robust, very lengthy, uh, relatively expensive randomized clinical trial that we launched back in 2018, and we're wrapping up this year to demonstrate that evidence. And we did have an interim analysis with early data that showed that we're on the right track. So we listened to the physicians, which has made this journey lengthy and challenging.

SPEAKER_00But that barrier to adoption and success early has led us to be an extremely robust data-driven company, which is going to do the best by the patients to actually get this adopted at a deep level.

SPEAKER_02So let's, if you don't mind, we could spend a little time here because it sounds like this has truly set the direction for kind of the last five, six, actually more, eight years of your company. Now let's forget it's 2026 by now. So when you say listening to physicians, right, this is something people often talk about. And one of the goals for this podcast is that people hear it and can kind of take something to their own organization, right? So how are you, when did that first surface? How did that surface? And then how did you? I'm sure there was a lot of exploration before you decided, yes, we're going to do this very long, very expensive clinical trial operationally.

SPEAKER_02How did that all come about?

SPEAKER_00It started probably with one of our first advisors. So I'd inherited a small advisory board went to go with the company. Namely, there was a physician named Dr. Daniel von Hoff. Dr. Dan von Hoff, based in Arizona, I'd consider one of the godfathers of pancreatic cancer treatment. He was the principal investigator of a braxane or the current standard of care of the combination of gemcitobine plus a braxine for pancreatic cancer. He was a PI for that study, got that approved, and that's still the standard of care. That was back in 2013. Previously, he was probably one of the leading investigators at all the work on gemsidobine, which is still the backbone and standard of care for many tumors, specifically in pancreatic cancer.

SPEAKER_00So he was definitely the guy or the person and on our advisory board. And he was lukewarm on what we're doing. In fact, uh soon after I took over as CEO, he resigned from the advisory board. And I think part of it was because he was pushing us, saying, look, you need a randomized trial. And we're a very tiny company, very minimally funded by family offices and more, more angel investors. And the board said, There's no way we're doing this. In fact, one of the board members said, Over my dead body, will you do a large expensive clinical trial? They were looking for a prick flip. It's like, here's a device, get the FTA clearance, show it works in patients, and sell this off to Medronic for a good return for the investors.

SPEAKER_00And move on to the next one for them. Yeah, exactly. Move on the next one. So Dr. Dan von Hoppe was pretty adamant that this is what you need to do. And he's the one who drives and pushes the new therapies forward, especially in pancreatic cancer. So that's where it started. And then from there, we did reach out to many oncologists. We went for the Pancratic Cancer Action Network, uh, PanCan as a big apacity group. There were tied in a lot of physicians. We met through them, for example, Dr. Michael Pischfeyen, who they recommended, and we pulled in, who's been the principal investigator for our phase three tiger pack study. So between Dan and uh Dr.

SPEAKER_00Von Hoff and Dr. Pishbeyen, we started to put our heads around what does a colour trial look like and pulled it in more of the qualities on the medical oncology side. It was a couple positions for allowed the beginning, and then we really did some research to see what's needed.

SPEAKER_02And so I'm always fascinated by this because something of having an idea, but then in any organization, usually there's not just one person that can say yes, right? Like you're the CEO, and even you can't pull the trigger yourself, right? You need to go and build consensus and get buy-in. So ultimately, we know there's no drama here. You ended up doing the trial. That same person who said over my dead body. Are they were they still involved in that decision to go through, or had they moved on to other investments at that point off the board or whatever?

SPEAKER_00That person was still involved and actually remained on our board for several years there after until you moved out of the country back back to his home countries. So, how did you go about building consensus for this when you have such direct opposition? Out of need, honestly. It was a necessity that this is the only way to make this company successful. It's gonna be a longer time horizon, it will be more expensive, it'll take more investments, it'll take more dilution. But on the flip side, this is a much bigger story. So having that study been done, we have two choices. We close the company down and run out of money, or we decide to embark on a bigger mission with potential bigger return that's gonna be pushed out later.

SPEAKER_00And that's we've made a lot of decisions along the way where you have a choice. You have uh death or cliff, or you build something bigger and greater and better for patients and for medicine. So I'm very lucky that those are the two choices becomes very obvious to me quickly, and then eventually I gain consensus.

SPEAKER_02But it is, I mean, even from an investor standpoint, it sounds like what you're talking about is trying to become the new standard of care, right? So it's that's a different level of hopefully impact and success and all of that. And then it's almost the need to force a decision of are we going forward or are we not? And it sounds like there's some pretty real implications of the answer is no. That's really interesting. The other piece, so we haven't really talked about your technology much, but it's my understanding is that it's essentially like a hyper-localized drug delivery system, delivering the drugs directly onto the tumors themselves.

SPEAKER_02Is that accurate or am I off there?

SPEAKER_00You're spot on. And then specifically with our technology, we're focusing on tumors that don't have large blood supplies, which is the barrier to success in current therapies. If you look at liver cancer, for example, the the tumors and liver cancers are really balls of blood vessels that are feeding these tumor cells. So you can easily reach them by giving systemic chemo. As much as you get side effects, it does reach there. And other tumors like pancreatic tumors, some non-small cell lung cancer, bile duct cancer, certain brain tumors, several others, they don't have a high-level blood supply.

SPEAKER_00And more specifically, they don't have very large blood vessels that feed them. So when you give systemic chemotherapy, it circulates the whole body but doesn't reach the tumor. We've developed, invented, and patented a new mechanism where we push drug across the wall of the blood vessel to bathe the tumors in chemo locally. So it is, like you mentioned, dropping chemo almost right on top of the tumor and then saturating the tumor and chemo. And that's where we're seeing success on not just reducing systemic levels, but also really driving high concentrations of drug at the tissue site.

SPEAKER_01If you've been enjoying the conversations here on Pharma Sessions, you should know they're made possible by the team at Xunt. Xunt helps life sciences companies turn complex data into clear, actionable insight. For years, Xunt has made complicated data sets simple to help commercial, medical, and operations teams map what's happening, predict what's next, and make stronger decisions faster. And now there's an added AI layer that makes everything work so much better. I was actually pretty jaded about some of the AI approaches I'd seen, but when Xunt showed me theirs, I actually left my job to come work for them.

SPEAKER_01It's really awesome. So if you want to understand your market, your customers, or your performance with more clarity than ever, check out xcent.com. That's xsunt.com. All right, let's jump back into the episode.

SPEAKER_02So I'm curious if this type of technology, even outside of oncology, is picking up speed elsewhere. Because just like two weeks ago, I posted an episode with a guy actually in California, you should hang out with him. He's really, really a very cool guy. Similar story, a 16-year journey of starting this company in the Durham space, but almost the same mechanism of I have a wound on my foot, I'm a diabetic patient, I have no blood flow down there. If I can deliver medicines directly there, rather it gets no blood flow.

SPEAKER_02It's similar, but obviously a different space, different. Is this a trend overall, like across medicine, or is this something that you're seeing a lot of these days?

SPEAKER_00It's interesting you you asked about trend because I feel like if MLN is successful and we're starting to see the successes now, this will become more of a trend. I'm actually shocked that it hasn't been a trend, especially if you look at things like chemotherapy. In fact, I remember talking to an advisor years ago, and they said, you know, look back like 50 years from now, it'd be less than that time, and think about how barbaric we were. You know, how do you treat this ailment? Well, you blast the entire body with poison and hope some gets the tumors. Nope, not the way to go. So for whatever reason, we haven't really focused on this. And I think part of it for tumors like pancreatic cancer tumors is that there hasn't been a way to do it.

SPEAKER_00There hasn't been a mechanism or development or technology to do it. So we stumbled upon this to some degree, but then really researched and figured out, okay, this is how you get drugs there. So I do see that trending more. There's been a lot of focus on precision medicine, on targeting molecular pathways and/or therapeutics to target specifically. But the problem is you still deliver those systemically. So there is a little bit more of a trend for local deliveries and technologies, but probably not enough.

SPEAKER_02Let's kind of continue this, right? Because you're talking about Bring this to market with a very science-first, evidence-based approach. In your career, as you alluded to earlier, you talked about a lot of cross-functional experience with clinical research, regulatory sales, physician training. The med device guys are always in the surgery rooms, right? Operating with people. Do you think that's helpful in developing messaging, developing marketing materials, a commercialization strategy for something that is actually a pretty innovative way to treat pancreatic cancer?

SPEAKER_00Absolutely. I strongly believe you've got to be on site with physicians to really understand what the market is. And that's part of the early part of my career that I'm lucky and glad my mentors pushed me towards. When they push me to go do sales to learn how to build technologies and build companies someday, now I truly understand. It's to understand what it takes to have a sales rep in an operating room andor a hospital convince a physician to change practice patterns. You got to know where the physician comes from. And you can't do that by reading a book or reading a brochure or reading uh or zooming in here and there.

SPEAKER_00Uh, it really takes the hands-on, face-to-face learning. And that's one of the reasons why when we commercialized the device last year, this the whole sales program was driven primarily by me and my head of strategy out in the field with physicians before we put a sales force in place. So, really truly understanding what the market is. And given my background, I've done that so many times in my career. I know what it takes, but I've got to see it and touch it and feel it firsthand to know what the right pathway is sometimes. And how many people do you have? Uh, how many people are in your sales force now? So we're still small. So we put in place uh three reps last year and ahead of marketing.

SPEAKER_00We're gonna add a couple more this year. And what I learned last year is you don't need a sales force of 10, 20, 30 people and burn a ton of capital and kind of eat up shareholder value there for the type of market that we're focusing on. Again, it's about doing things the right way and the efficient way that that gets you the results.

SPEAKER_02Yeah, it's funny. Now I'm just gonna talk about my personal problems here, but I have a very small sales and marketing team that I'm leading at my company. And when you talk about efficiency, sometimes things feel so inefficient doing setting up systems and doing things for a team of five people versus even 15 people would would feel really, really different. Where it's like, oh, am I just doing this for this one person? You know, so how do you manage that, right? Like you need systems, you need to operate to certain standards, but also when you're we are supporting such a small team, it can be sometimes easier, faster to just have direct one-on-one conversations with people.

SPEAKER_00It's challenging, and that's one thing I learned as a CEO that that one of my mentors, who's actually the founder of my company, Dr. Ram Tagal, mentioned I'm so used to being hands-on and so used to learning and directing and being communicative with the entire team. He told me a couple of years ago, he's like, Be careful what you say to people aren't directly beneath you, uh, because it carries a lot of weight when the CEO says something versus, for example, a manager says something. And I didn't realize that because I feel like we're all on the same team, we're all on the same battlefield. As much as our money in the company, we roll our sleeves up, be down to the same levels.

SPEAKER_00Uh, but when an executive says something to, let's say, an intern or like maybe a junior person or entry-level person, as much as it's more efficient than going through a couple layers of management, it can come off a little bit stronger and a little bit scary sometimes and maybe not produce the right results. So it is a challenge to balance that.

SPEAKER_02Or you might even be talking out loud, right? Ideating, and they're taking that as direction, right? And you're accidentally shifting trajectories without meaning to. That's really interesting. So let me ask, because you brought up the idea of relationships, I fully believe that is a great thing. I mean, honestly, that's why I do this podcast is to make relationships, but a world that's all AI, right? All the Super Bowl commercials were AI, everything's AI and digital. You're talking a lot about is the importance of face-to-face relationships with the doctors or with your colleagues.

SPEAKER_02Do you think that that approach can be an actual competitive advantage when you're thinking about healthcare leadership? When you say advantage of using AI or not using AI, the advantage of, I guess, over-indexing on face-to-face, right? Like of actually creating meaningful relationships with people. In your case, a doctor is going to be like, Yeah, I'm never going to prescribe that unless you show me the evidence, or I'm never going to use that unless you show me the evidence, right? That to me, pre-COVID, I was always going to these pharma companies and meeting with them. And I feel like you'd have the meeting and it would go well or wouldn't go well, whatever.

SPEAKER_02And then on the walk back to the elevator, when you're walking out of the door, that's when they would tell you what would was really happening. And I think that that is the hardest thing that to replicate with digital with AI.

SPEAKER_00100%, John. That's one of the reasons I even during COVID, uh, when we were at shelter in place and on lockdown, I was still on a plane probably once a month. In fact, I remember flying to Belgium for one of our physical trial procedures and had to get permission from the embassy, from the government, uh, had a letter from the CL hospital, and I was probably one of 10 passengers on a jumbo jet flying across across the ocean. It was an empty city. The hotel was closed except for uh, I think it's four or five rooms, and the restaurant was open for those four or five people there.

SPEAKER_00And I've always valued that face-to-face and and that because you're 100% correct. It's I've always gotten more things. You mentioned the elevator, because I've probably got more meetings done successfully on that elevator walk or the parking lot walk or the rating and line for a coffee together when you meet for a coffee type situations where you really truly understand what's going on, what the potential pushback is or opportunities. And you can't get that on Zoom. I mean, this, for example, as much as this would be fun in person, it is efficient. And being public company, for example, when we went public, I was able to handle even in previous fundraisings 10, 20, 30, 40, 50 roadshow meetings in the course of three days, which used to be a lot of airplanes and taxis and shuttles uh that you have to do over several weeks.

SPEAKER_00So there is a little bit efficiency, but I try to balance that with jumping back on a plane and whenever there's an opportunity to go meet people face to face to get the best of both worlds.

SPEAKER_02Absolutely. Well, we will at some point when you're on the East Coast or I'm on the West Coast, we'll make it happen. And uh so let me just wrap up with one final question here because I feel like it's something that you alluded to a couple of times, and but it's this idea of making a big jump, right? You talked about having a family that has a bunch of doctors in it and then getting into medical school. I'm sure there's some pressures for you to then go and do medical school, right? You talk about going from larger company acquired by Medtronic, right?

SPEAKER_02Whatever headwinds are you're you're facing, that's still very different than a two-person company. So if you had any words of advice for people that might find themselves in similar moments of should I take a leap, what would you say to them?

SPEAKER_00I'd say do it is my gut response, but that's my personality. And then and then my my second response is uh it depends on the person, honestly. Some people are are comfortable with these tough decisions and taking the path less traveled. And I've been lucky, it drives me. I get bored easily if I don't, if I'm not challenged enough. And med school is one of them. I believe for the universities I chose, I picked the right fit that I thought would be a good balance on both success and learning and communication skills. And I picked the least ranked school that I got into for undergrad.

SPEAKER_00I declined med school when I got there. I left the big company when my boss said, Look, you're a senior sales Medtronic making a lot of money. Uh, people retire with this type of position. It's very coveted to have this. It takes a lot to get to a position like this, and you're taking a big risk by going to a startup company. But I wasn't passionate about not having an impact every day on medicine and then even taking on this role 11 and a half years ago. I thought I wanted to learn more on the management side before I jump into a CEO role. So I wanted to kind of build out my career more, but the opportunity was here and the potential impact on cancer was here.

SPEAKER_00So I took that leap. So I've had several pathways. We went public in 2021, with when I had previous people tell me never become a public company CEO is so worse, stressful, uh, especially in the microcap space, headache job you could have, but it's afforded us the opportunity to survive and thrive in an in an environment where companies are closing down because they couldn't get funding. So I feel like I've taken so many paths less traveled. My advice to others are seek uh mentorship and guidance about a lot of friends, family, and mentors I built over the years to kind of use these sounding boards on this is the type of stuff I'm thinking about with this decision versus not.

SPEAKER_00And eventually, trust your gut, you come to the right decision. If you think about it, talk to people and see what aligns with your personality and what the best chance for success is. I love it. All right. Well, let's leave it there. Sean, thank you so much for joining me today.

SPEAKER_02Appreciate it, John. I'm great to catch up. Looking forward to that coffee or beer in person at some point. Absolutely. This episode of Pharma Sessions is sponsored by Xunt, makers of the X1 reporting platform. And that's a wrap on today's episode of Pharma Sessions with me, Jonathan Kaske. If you enjoyed today's conversation, don't forget to hit follow or subscribe and share it with someone else in the pharma world who might need to hear it. For more on pharma trends, career growth, and business strategies, connect with me, Jonathan Kaske, on LinkedIn.

SPEAKER_02Until next time, thanks for listening.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode